0001470831-25-000015.txt : 20250506 0001470831-25-000015.hdr.sgml : 20250506 20250506092720 ACCESSION NUMBER: 0001470831-25-000015 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 EFFECTIVENESS DATE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CERO THERAPEUTICS HOLDINGS, INC. CENTRAL INDEX KEY: 0001870404 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 871088814 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-545301 FILM NUMBER: 25915636 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY STREET 2: SUITE 230 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-407-2376 MAIL ADDRESS: STREET 1: 201 HASKINS WAY STREET 2: SUITE 230 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: PHOENIX BIOTECH ACQUISITION CORP. DATE OF NAME CHANGE: 20210630 D 1 primary_doc.xml X0708 D LIVE 0001870404 CERO THERAPEUTICS HOLDINGS, INC. 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 650-407-2376 DELAWARE PHOENIX BIOTECH ACQUISITION CORP. Corporation true 2021 Chris Ehrlich 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Chairman and Chief Executive Officer Andrew Albert Kucharchuk 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Executive Officer Chief Financial Officer Kristen Pierce 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Executive Officer Chief Development Officer Brian G. Atwood 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Michael Byrnes 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Kathleen LaPorte 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Shami Patel 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Lindsey Rolfe 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Pharmaceuticals No Revenues 06b false 2025-04-22 false true false 0 8000000 5000000 3000000 Pursuant to a Securities Purchase Agreement, dated 4/21/2025, up to 10,000 shares of the Company's Series D convertible preferred stock, par value $0.0001 per share shall be purchased for an aggregate purchase price of up to $8M in one or more closings. false 5 0 0 0 false CERO THERAPEUTICS HOLDINGS, INC. /s/ Andrew Kucharchuk Andrew Kucharchuk CFO 2025-05-06